OHR Pharmaceutical, Inc. (OHRP) EPS Estimated At $-0.07; PUBLICIS GROUPE (PGPEF) Shorts Down By 0.11%

January 16, 2018 - By Linda Rogers

Analysts expect OHR Pharmaceutical, Inc. (NASDAQ:OHRP) to report $-0.07 EPS on February, 13.They anticipate $0.14 EPS change or 66.67% from last quarter’s $-0.21 EPS. After having $-0.08 EPS previously, OHR Pharmaceutical, Inc.’s analysts see -12.50% EPS growth. The stock increased 4.27% or $0.014 during the last trading session, reaching $0.342. About 1.02M shares traded. OHR Pharmaceutical, Inc. (NASDAQ:OHRP) has declined 77.87% since January 16, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.

PUBLICIS GROUPE (OTCMKTS:PGPEF) had a decrease of 0.11% in short interest. PGPEF’s SI was 1.92M shares in January as released by FINRA. Its down 0.11% from 1.93M shares previously. With 1,400 avg volume, 1374 days are for PUBLICIS GROUPE (OTCMKTS:PGPEF)’s short sellers to cover PGPEF’s short positions. The stock increased 6.34% or $4.2536 during the last trading session, reaching $71.3636. About 2,350 shares traded. Publicis Groupe S.A. (OTCMKTS:PGPEF) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 3 analysts covering Ohr Pharma (NASDAQ:OHRP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Ohr Pharma had 6 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, January 5 by Roth Capital. The firm has “Buy” rating given on Thursday, October 27 by H.C. Wainwright. The rating was downgraded by Brean Capital to “Hold” on Wednesday, August 10. The stock of OHR Pharmaceutical, Inc. (NASDAQ:OHRP) earned “Buy” rating by H.C. Wainwright on Wednesday, August 16. The firm has “Buy” rating by Brean Capital given on Friday, August 7.

Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.19, from 1.25 in 2017Q2. It increased, as 3 investors sold OHR Pharmaceutical, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 4.60 million shares or 16.87% more from 3.93 million shares in 2017Q2 were reported. California Pub Employees Retirement Systems stated it has 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Wells Fargo Mn holds 834 shares. Bankshares Of Ny Mellon owns 34,472 shares or 0% of their US portfolio. Moreover, Creative Planning has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 61,000 shares. Garrison Bradford And Inc holds 0.3% or 497,415 shares. Cutter And Brokerage Inc owns 38,875 shares or 0.01% of their US portfolio. Janney Montgomery Scott Ltd Com holds 10,500 shares. Leisure Capital holds 0.04% or 64,067 shares in its portfolio. United Fin Advisers Ltd Llc holds 86,422 shares. Finemark Comml Bank Tru invested in 0% or 22,589 shares. Virtu Limited Liability Company holds 33,345 shares. Two Sigma Securities Llc, New York-based fund reported 21,733 shares. Salzhauer Michael accumulated 35,715 shares. Hightower Advisors Ltd Liability Corp holds 27,000 shares. Neuberger Berman Group Ltd Limited Liability Company reported 46,176 shares.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $19.23 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: